zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2023 / The board of directors of the Company approved removal of the noncompete clause for managers.

The board of directors of the Company approved removal of the noncompete clause for managers.

2023-04-12

Published Date:2023-04-12

Original Link:https://www.onenessbio.com/en/news_detail211_4.htm

No 1 Date of announcement 2023/04/12 Time of announcement 16:58:54
Subject The board of directors of the Company approved removal of the noncompete clause for managers.
To which item it meets paragraph 21 Date of events 2023/04/12
Statement
  1. Date of the board of directors resolution:2023/04/12
  2. Name and title of the managerial officer with permission to engage in competitive conduct:The general president, Chih-Hui Cheng.
  3. Items of competitive conduct in which the officer is permitted to engage:
    (1)Director of the Microbio (Shanghai) Co., Ltd.(Representative Director of the Oneness Biotech Co., Ltd.)
    (2)Director of the Microbio Singapore Pet. Ltd.(Representative Director of the Oneness Biotech Co., Ltd.)
  4. Period of permission to engage in the competitive conduct:For the duration of employment as a manager of the Company.
  5. Circumstances of the resolution (please describe the results of voting in accordance with Article 32 of the Company Act):The board of directors approved the proposal unanimously with no changes.
  6. If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and  title of the managerial officer (if it is not the operator of a mainland China enterprise, please enter “N/A” below):The general president, Chih-Hui Cheng.
  7. Company name of the mainland China enterprise and the officer’s position in the enterprise:Director and Financial Officer of the Microbio(Shanghai) Co., Ltd.
  8. Address of the mainland China enterprise:1188 Guangxing Road,Songjiang District, Shanghai China.
  9. Operations of the mainland China enterprise:Production and sales of health care capsules and lozenges, Chinese herbal medicines, Chinese herbal extracts, Chinese patent medicine processing and production, new drug research and development, etc.
  10. Impact on the company’s finance and business:
    Microbio (Shanghai) is invested by the Company by adopting the equity method through which the profits or losses is recognized.
  11. If the managerial officer or director has invested in the mainland China enterprise, the monetary amount of the investment and the officer or director’s shareholding ratio:
    (1) The monetary amount of the investment: USD 372,000.
    (2) The shareholding ratio: 0.7094%.
  12. Any other matters that need to be specified:None.